Disposition of 327 shares by Eric Hsu of InMed Pharmaceuticals at 499.96 subject to Rule 16b-3
| 6123 Stock | TWD 56.00 0.80 1.41% |
Slightly above 61% of GrandTech's investor base is looking to short. The analysis of current outlook of investing in GrandTech CG Systems suggests that many traders are alarmed regarding GrandTech's prospects. GrandTech's investing sentiment can be driven by a variety of factors including economic data, GrandTech's earnings reports, geopolitical events, and overall market trends.
GrandTech stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of GrandTech daily returns and investor perception about the current price of GrandTech CG Systems as well as its diversification or hedging effects on your existing portfolios.
GrandTech |
Filed transaction by InMed Pharmaceuticals Officer Sr. Vp, Pre-clinical Resdev. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
Read at macroaxis.com
GrandTech Fundamental Analysis
We analyze GrandTech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GrandTech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GrandTech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Profit Margin
Profit Margin Comparative Analysis
GrandTech is currently under evaluation in profit margin category among its peers. Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
GrandTech CG Systems Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with GrandTech stock to make a market-neutral strategy. Peer analysis of GrandTech could also be used in its relative valuation, which is a method of valuing GrandTech by comparing valuation metrics with similar companies.
Peers
GrandTech Related Equities
| 4130 | Genovate Biotechnology | 0.23 |
| ||
| 4109 | Jia Jie | 1.45 |
| ||
| 6569 | Onyx Healthcare | 1.62 |
| ||
| 3176 | Medigen Biotechnology | 2.15 |
| ||
| 4192 | SynCore Biotechnology | 2.79 |
|
Additional Tools for GrandTech Stock Analysis
When running GrandTech's price analysis, check to measure GrandTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GrandTech is operating at the current time. Most of GrandTech's value examination focuses on studying past and present price action to predict the probability of GrandTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GrandTech's price. Additionally, you may evaluate how the addition of GrandTech to your portfolios can decrease your overall portfolio volatility.